CARGO TherapeuticsCRGX
About: Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
Employees: 170
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
217% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 12
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
21% more capital invested
Capital invested by funds: $717M [Q2] → $865M (+$148M) [Q3]
8% more funds holding
Funds holding: 73 [Q2] → 79 (+6) [Q3]
6.77% more ownership
Funds ownership: 95.19% [Q2] → 101.96% (+6.77%) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 36 / 155 met price target | 121%upside $33 | Buy Reiterated | 15 Nov 2024 |
Chardan Capital Geulah Livshits 17% 1-year accuracy 8 / 48 met price target | 88%upside $28 | Buy Maintained | 13 Nov 2024 |
Financial journalist opinion
Based on 3 articles about CRGX published over the past 30 days
